pharma · Moderate to Severe Platysma Prominence · Chronic migraine
Merz Therapeutics
Merz Therapeutics GmbH
Merz Therapeutics is a pharma organization headquartered in EU. Primary therapeutic focus areas include Moderate to Severe Platysma Prominence, Chronic migraine, Episodic migraine. NovaPharmaNews links 3 clinical program
frankfurt am main, DE HQ
2020 Founded
1,312 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- frankfurt am main, DE
- Founded
- 2020
- Employees
- 1,312
- Programs
- 3
- Drugs
- 5
- Patents
- 0
NT-PPR-EU002
Phase 3 · small molecule · Moderate to Severe Platysma Prominence
NT-PPR-EU002 for Moderate to Severe Platysma Prominence is a Phase 3 program (small_molecule) at Merz Therapeutics GmbH with 1 ClinicalTrials.gov record(s).
Internal code NT-PPR-EU002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Merz Therapeutics GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Moderate to Severe Platysma Prominence
- Status
- active
- Trials
- 1